ACE-031

ACE-031

Also known as: ACVR2B-Fc, Myostatin Inhibitor

ACE-031 is an experimental agent that inhibits the myostatin and activin signaling pathways, initially created to enhance muscle growth and improve muscle function. As a recombinant fusion protein, it works by attaching to and blocking myostatin and other related proteins that restrict muscle development, which may lead to greater muscle mass and strength. The compound attracted research interest in areas such as muscle-wasting conditions, muscular dystrophy, athletic performance enhancement, and tissue regeneration, but its clinical development was later halted.

Key research areas associated with ACE-031 include:
– Pathways involved in muscle growth and hypertrophy
– Inhibition of myostatin
– Studies on muscle-wasting diseases
– Research on strength and physical performance
– Applications in regenerative medicine

• Status: Development discontinued due to safety concerns. Evidence based on animal studies.
• Standard dosage: Insufficient community data; refer to established research protocols. Administered via subcutaneous injection.
• Investigated for: Research on muscle growth and treatment of muscular dystrophy.